Objective: To observe the clinical efficacy of L-asparaginase (L-Asp) and pegaspargase (PEG-Asp) in the treatment of children with acute lymphoblastic leukemia. Methods: Totally 103 children with acute lymphoblastic leukemia admitted into Linyi Traditional Chinese Medicine Hospital from May 2017 to Aug. 2018 were extracted

the clinical and follow-up data of all children were analyzed retrospectively. According to different treatment drugs

all children were divided into the L-asparaginase group (group L

51 cases) and the pegaspase group (group P

52 cases). Group L was treated with L-Asp every 6

000 U/m2 intravenous injection

group P received PEG-Asp every 2

500 IU/m2 intramuscular injection. Efficacy

length of stay

coagulation dysfunction

liver function and adverse drug reactions after treatment of two groups were compared. Results: The level of alanine aminotransferase showed an increasing trend in both groups (P<0.01)

while the level of alanine aminotransferase in group P was lower than that in group L (P<0.05). The level of albumin in two groups showed a downward trend (P<0.05). The level of total bilirubin in both groups showed an upward trend (P<0.05). After treatment

the incidence of allergic reaction and pancreatitis in group L was higher than that in group P (P<0.05). Conclusion: PEG-Asp in the treatment of children with acute lymphoblastic leukemia can relieve the disease of children more quickly

with fewer times of administration

shorter length of stay and lower incidence of allergic reaction than L-Asp

but higher incidence of pancreatitis than L-Asp

and the safety of PEG-Asp should be further studied and discussed.